CY1120516T1 - Θεραπειες για τον καρκινο - Google Patents
Θεραπειες για τον καρκινοInfo
- Publication number
- CY1120516T1 CY1120516T1 CY20181100519T CY181100519T CY1120516T1 CY 1120516 T1 CY1120516 T1 CY 1120516T1 CY 20181100519 T CY20181100519 T CY 20181100519T CY 181100519 T CY181100519 T CY 181100519T CY 1120516 T1 CY1120516 T1 CY 1120516T1
- Authority
- CY
- Cyprus
- Prior art keywords
- cancer
- treatment
- nuc
- stem cells
- cancer stem
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
- G01N33/57595—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving intracellular compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/GB2015/051438 WO2016181093A1 (en) | 2015-05-14 | 2015-05-14 | Cancer treatments |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1120516T1 true CY1120516T1 (el) | 2019-07-10 |
Family
ID=53276184
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20181100519T CY1120516T1 (el) | 2015-05-14 | 2018-05-18 | Θεραπειες για τον καρκινο |
Country Status (26)
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0317009D0 (en) | 2003-07-21 | 2003-08-27 | Univ Cardiff | Chemical compounds |
| DK3031812T3 (en) | 2011-03-01 | 2018-09-17 | NuCana plc | CHEMICAL COMPOUNDS |
| SI3150616T1 (sl) | 2012-11-16 | 2017-08-31 | University College Cardiff Consultants Limited | Mešanica rp/sp gemcitabin-(fenil-(benziloksi-l-alaninil))-fosfata |
| WO2015198059A1 (en) | 2014-06-25 | 2015-12-30 | Nucana Biomed Limited | Formulation comprising a gemcitabine-prodrug |
| EP3160978B1 (en) | 2014-06-25 | 2020-07-29 | NuCana plc | Gemcitabine prodrugs |
| GB201417644D0 (en) | 2014-10-06 | 2014-11-19 | Nucana Biomed Ltd | Method of separating phosphate diastereoisomers |
| LT3224268T (lt) | 2014-11-28 | 2019-09-25 | NuCana plc | Naujieji 2` ir (arba) 5` aminorūgšties esterio fosforamidato 3`-deoksi adenozino dariniai, kaip priešvėžiniai junginiai |
| BR112018003594A2 (pt) | 2015-09-25 | 2018-09-25 | Hoffmann La Roche | cadeia pesada de imunoglobulina recombinante, anticorpos, método de produção de conjugado e conjugados |
| PH12018500691B1 (en) | 2015-10-05 | 2022-08-10 | NuCana plc | Combination therapy |
| RS62593B1 (sr) | 2015-12-11 | 2021-12-31 | NuCana plc | Dijastereoselektivna sinteza derivata fosfata i proleka gemcitabina nuc-1031 |
| HUE050290T2 (hu) * | 2015-12-23 | 2020-11-30 | NuCana plc | Kombinált terápia |
| GB201522771D0 (en) | 2015-12-23 | 2016-02-03 | Nucana Biomed Ltd | Crystalline form of a phosphate derivative |
| CA3008769A1 (en) * | 2015-12-23 | 2017-06-29 | NuCana plc | Combination therapy comprising nuc-1031 and cisplatin |
| GB201609600D0 (en) * | 2016-06-01 | 2016-07-13 | Nucuna Biomed Ltd | Cancer treatments |
| GB201709471D0 (en) | 2017-06-14 | 2017-07-26 | Nucana Biomed Ltd | Diastereoselective synthesis of hosphate derivatives |
| GB201713916D0 (en) * | 2017-08-30 | 2017-10-11 | Nucana Biomed Ltd | Treatment regimens |
| EP3863674A2 (en) | 2018-10-12 | 2021-08-18 | The Regents of the University of Colorado, a body corporate | Compositions and methods for reducing cancer stem cells |
| CN117462555B (zh) * | 2021-01-31 | 2025-12-30 | 兰州大学 | 6-巯基鸟嘌呤在制备预防和/或治疗酒精性胃溃疡药物中的应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0317009D0 (en) | 2003-07-21 | 2003-08-27 | Univ Cardiff | Chemical compounds |
| HRP20160625T1 (hr) * | 2007-09-10 | 2016-08-12 | Boston Biomedical, Inc. | Novi inhibitori stat3 signalnog puta i inhibitori matičnih stanica raka |
| EP2274617A4 (en) * | 2008-04-10 | 2011-11-09 | Massachusetts Inst Technology | METHOD OF DETECTING AND USING MEDIUM-TREATMENT AID ON CANCER STEM CELLS |
-
2015
- 2015-05-14 SM SM20180303T patent/SMT201800303T1/it unknown
- 2015-05-14 US US15/573,969 patent/US20180289733A1/en not_active Abandoned
- 2015-05-14 CN CN202310013004.2A patent/CN115837028A/zh not_active Withdrawn
- 2015-05-14 HU HUE15726258A patent/HUE038541T2/hu unknown
- 2015-05-14 MX MX2020009154A patent/MX390506B/es unknown
- 2015-05-14 ES ES15726258.5T patent/ES2668377T3/es active Active
- 2015-05-14 WO PCT/GB2015/051438 patent/WO2016181093A1/en not_active Ceased
- 2015-05-14 KR KR1020177035629A patent/KR20180021697A/ko not_active Ceased
- 2015-05-14 EP EP15726258.5A patent/EP3197456B2/en active Active
- 2015-05-14 JP JP2018511527A patent/JP6761852B2/ja not_active Expired - Fee Related
- 2015-05-14 HR HRP20180762TT patent/HRP20180762T1/hr unknown
- 2015-05-14 PT PT157262585T patent/PT3197456T/pt unknown
- 2015-05-14 TR TR2018/06642T patent/TR201806642T4/tr unknown
- 2015-05-14 CN CN201580081668.6A patent/CN107835687A/zh active Pending
- 2015-05-14 CA CA2985540A patent/CA2985540C/en active Active
- 2015-05-14 RS RS20180575A patent/RS57371B1/sr unknown
- 2015-05-14 LT LTEP15726258.5T patent/LT3197456T/lt unknown
- 2015-05-14 EA EA201792509A patent/EA201792509A1/ru unknown
- 2015-05-14 MX MX2017014544A patent/MX374946B/es active IP Right Grant
- 2015-05-14 EP EP18164408.9A patent/EP3415149A1/en not_active Withdrawn
- 2015-05-14 PH PH1/2017/502086A patent/PH12017502086B1/en unknown
- 2015-05-14 AU AU2015394135A patent/AU2015394135B2/en not_active Ceased
- 2015-05-14 DK DK15726258.5T patent/DK3197456T3/en active
- 2015-05-14 MY MYPI2017001657A patent/MY192081A/en unknown
- 2015-05-14 SI SI201530240T patent/SI3197456T1/en unknown
- 2015-05-14 PL PL15726258T patent/PL3197456T3/pl unknown
- 2015-05-14 BR BR112017024461-6A patent/BR112017024461B1/pt not_active IP Right Cessation
-
2017
- 2017-11-12 IL IL255591A patent/IL255591B/en unknown
-
2018
- 2018-05-18 CY CY20181100519T patent/CY1120516T1/el unknown
-
2020
- 2020-09-22 US US17/028,314 patent/US20210100825A1/en not_active Abandoned
-
2021
- 2021-11-30 AU AU2021277614A patent/AU2021277614A1/en not_active Abandoned
-
2022
- 2022-08-08 US US17/883,472 patent/US20230226092A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1120516T1 (el) | Θεραπειες για τον καρκινο | |
| CY1123983T1 (el) | Ειδικα σε axl συζευγματα αντισωματος-φαρμακου για τη θεραπεια καρκινου | |
| EA201691931A1 (ru) | 4'-замещенные нуклеозидные ингибиторы обратной транскриптазы | |
| SA520411108B1 (ar) | مركبات حلقية كبيرة واستخداماتها | |
| EA201891200A1 (ru) | Композиции, содержащие бактериальные штаммы | |
| JOP20190194A1 (ar) | مركبات نيوكليوتيدات ثنائية حلقية لعلاج السرطان | |
| MX380907B (es) | Compuestos útiles como inhibidores de cinasa. | |
| EA201892802A1 (ru) | Производные аденозина для применения при лечении рака | |
| EA201790597A1 (ru) | Способы лечения вирусных инфекций filoviridae | |
| BR112018070163A2 (pt) | compostos de aminopurina substituída, composições e métodos de tratamento | |
| EA201791867A1 (ru) | Бициклические гетероциклы как ингибиторы fgfr4 | |
| EA201591599A1 (ru) | Ингибиторы ido | |
| MX375716B (es) | Método para tratar adenocarcinoma de pulmón. | |
| EA201692091A1 (ru) | Хиноксалиновые соединения и их применение | |
| EA201891340A1 (ru) | Лечение рака с использованием 2-дезокси-2-фтор-l-фукозы в комбинации с ингибитором контрольных точек | |
| BR112017021312A2 (pt) | tratamento de câncer de pulmão com inibidores de glutaminase | |
| MX2020006365A (es) | Quinazolinonas como inhibidores de poli(adenosin difosfato-ribosa)polimerasa 14 (parp14). | |
| EA201892803A1 (ru) | Противоопухолевая терапия | |
| MX2020006297A (es) | Variantes de cd19. | |
| AU2015267099A8 (en) | Use of eribulin in the treatment of cancer | |
| EA201891527A1 (ru) | Композиции и способы обнаружения и лечения рака пищевода | |
| PH12018502242A1 (en) | Imidazolone compounds as human neutrophil elastase inhibitors | |
| EA201690376A1 (ru) | Ингибиторы дезоксицитидинкиназы | |
| EA201691896A1 (ru) | Соединения и способы их применения | |
| UA117455C2 (uk) | Спосіб лікування раку легенів із застосуванням інгібітора кінази аврора |